Avanafil tablets 50mg/100mg/200mg

MOA a PDE5 inhibitor 

Indication Erectile Dysfunction
Innovator Mitsubishi Tanabe Pharma,
Route of Tablets
Administration
Avanafil DCGI Approval 26.02.2021
Dosage 100 mg taken approximately 30 minutes before sexual
activity
Points

https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NzAzMw== 1
Market value
The global erectile dysfunction market size will be valued at USD 4.7 billion by 2026.
Oral drugs are found to be more effective and safe drugs and are considered first-line therapy
in the treatment of ED. Hence, these drugs account for over 94% share of the market
Retail pharmacies are projected to touch revenue figures of over $1.7 billion by 2026 due to
the increased accessibility and penetration of these stores.
The APAC region is projected to grow at the highest CAGR during 2020–2026 due to the
increase in the aging population and high incidence of diabetes, hypertension, and
cardiovascular diseases.
Over 50% and 51.3% of people with cardiovascular diseases and diabetes, respectively, are
likely to experience erectile dysfunction

2
Competitors Brands in Market (PDE5
Inhibitors)
Brand Active ingredients Company
Viagra sildenafil Pfizer
Cialis tadalafil lupin
Levitra vardenafil GSK
Manforce sildenafil Mankind
cavetra sildenafil sunpharma

3
Comparison
Avanafil (the active ingredient in Stendra) Sildenafil (the active ingredient in Viagra)
Off label Raynaud’s phenomenon Raynaud’s phenomenon
Female sexual arousal disorder,
pulmonary arterial hypertension (Only
when prescribed as Revatio)
Side Effect Less side effects More side effects
Standard
100 mg 50 mg
dosage
generic name Avanafil (but it is not yet available in Sildenafil
generic)
Most Adverse Less Chance of priapism More chance of priapism
effect

4
Avanafil Manufacturer in India
API  TABLETS
Akhil Healthcare Pvt Ltd.: Wellona Pharma- Gujarat
Aarambh Life Science: Kamagra supplers-Haryana
Manus Aktteva Biopharma LLP:
Merix Laboratories Pvt. Ltd.:
Hermes Chemical Company Private Limited:
Ultratech India Limited:
Honour Lab Limited:
MSN Laboratories: Hyderabad

5
conclusion
Although the oral drugs of ED lost their patent protection only a few sellers occupy the
dominant market share like Pfizer, Eli Lilly and Company, Bayer etc.
Drug market is expected to witness sustainable growth due to the high availability of generic
versions.
The competitiveness among vendors is significantly high because of the accessibility to a wide
range of low-cost generic drugs and OTC topical drug formulations for treating ED.